Rezolute Inc
NASDAQ:RZLT
Rezolute Inc
Revenue
Rezolute Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rezolute Inc
NASDAQ:RZLT
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$57.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$34.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
Rezolute Inc
Glance View
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 26 full-time employees. The company went IPO on 2011-12-23. The firm's lead clinical asset, RZ358, is an antibody therapy in Phase II b development as a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder. Its second clinical asset, RZ402, is a selective and potent Plasma Kallikrein Inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of Diabetic Macular Edema (DME), is in Phase I development. The clinical study conducting by the Company is called RIZE - An open-label multiple-dose study of RZ358 in Patients with Congenital Hyperinsulinism.
See Also
What is Rezolute Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2024, Rezolute Inc's Revenue amounts to 0 USD.
You don't have any saved screeners yet